BioVie Inc. Stock price

Equities

BIVI

US09074F2074

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.5286 USD -0.94% Intraday chart for BioVie Inc. -6.85% -58.05%
Sales 2024 * - Sales 2025 * - Capitalization 29.02M
Net income 2024 * -49M Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-0.52 x
P/E ratio 2025 *
-
Employees 18
Yield 2024 *
-
Yield 2025 *
-
Free-Float 56.72%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.94%
1 week-6.85%
Current month-57.37%
1 month-57.71%
3 months-56.49%
6 months-83.32%
Current year-58.05%
More quotes
1 week
0.48
Extreme 0.4812
0.60
1 month
0.48
Extreme 0.4812
3.31
Current year
0.48
Extreme 0.4812
3.31
1 year
0.48
Extreme 0.4812
8.69
3 years
0.48
Extreme 0.4812
23.86
5 years
0.00
Extreme 0
46.10
10 years
0.00
Extreme 0
68.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 16-04-10
Director of Finance/CFO 59 18-09-30
Chief Tech/Sci/R&D Officer 64 21-10-31
Members of the board TitleAgeSince
Director/Board Member 87 20-06-15
Director/Board Member 81 19-06-23
Chairman 59 15-12-31
More insiders
Date Price Change Volume
24-03-28 0.5286 -0.94% 778,922
24-03-27 0.5336 +0.47% 2,293,421
24-03-26 0.5311 -6.17% 863,144
24-03-25 0.566 -1.67% 1,299,093
24-03-22 0.5756 +1.43% 780,946

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
BioVie Inc. is a clinical-stage company engaged in developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions. In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a liquid formulation. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.5286
Average target price
-
Consensus
  1. Stock
  2. Equities
  3. Stock BioVie Inc. - Nasdaq